All Clinical Trials are full and no longer enrolling new patients
Past clinical trials are listed below:
Ultraclear CLINICAL TRIAL
CLOSED
Women and men 60+ years old with skin types 1-4 and perioral and cheek wrinkles.
Patients will be treated with Ultraclear, an FDA cleared laser using fractionated technology to help reverse signs of aging, including wrinkles, sun spots, scars and pigmentation.
Patients will be treated by a board certified dermatologist and will receive 3 Ultraclear treatments 6-8 weeks apart. Follow up visits will take place 1 and 3 months after the third treatment.
Call our office 713-900-3900 or email us: info@dermlasersurgery.com to see if you are a candidate!
Sofwave Clinical Trial
CLOSED
Clinical trial of a newly FDA cleared device using ultrasound technology. This device treats facial lines & wrinkles and lifts the brow and skin on the neck & submental region.
Participants Must:
- Be between the ages of 35-70
- Non -Smoker
- Desire to improve facial lines and wrinkles
- Has NOT had a facial skin-tightening procedure in the past year, including injectable fillers of any type
- Has NOT had Botox or other neuromodulators within the past 6 months
- Has NOT had any lasers rejuvenation treatments within the past 6 months
Please e-mail: info@dermlasersurgery.com or call 713-900-3900 and ask for Arely
Rosacea Study
CLOSED
Dr. Paul Friedman of Dermatology & Laser Surgery Center in Houston, TX is conducting a clinical trial, using the Vbeam Prima laser, to improve facial flushing, redness, and the appearance of visible blood vessels, when used in combination with a topical prescription cream (RHOFADE™ (oxymetazoline HCl) Cream, 1%) for erythematotelangiectatic rosacea.
The study treatment by the laser device heats the tiny, broken blood vessels on the face and should improve flushing and redness. The study will try to determine if the areas treated with the laser and the topical prescription cream will have improved outcomes, compared to what would have been obtained with the topical prescription cream alone. The VBEAM PRIMA device used in this study was recently cleared by the Food and Drug Administration (FDA). The topical prescription cream used in the study, Allergen’s RHOFADE™ (Oxymetazoline Hydrochloride) 1% Cream is FDA-cleared for the topical treatment of persistent facial erythema associated with rosacea in adults.
The treatment is a series of three treatments, each of which take about 15 minutes. Treatments are performed in the office. The trial is free and includes reimbursement of $75 for each tube of RHOFADE not covered by insurance.
Study candidates must meet the following criteria:
- Are a healthy male or female of 18 to 75 years of age
- Have erythematotelangiectatic rosacea with clinician erythema assessment (CEA) and subject self-assessment (SSA) of “moderate” or “severe”
- Are not undergoing any form of treatment for active cancer or do not have a history of skin cancer or any other cancer on the face
- Not pregnant or planning to become pregnant during the study duration
For more information about trial participation, please contact us: 713-900-3900
Melasma Study: laser combined with the tranexamic acid pill
CLOSED
Seeking healthy non-smoking male and female volunteers of all skin types of age 18 to 50 with moderate melasma or severe melasma. Participants will receive up to 5 monthly laser treatments to half the face and need to take a pill twice a day for 4 months. Follow up visits are required 1 month, 3 months and 6 months after the final treatment. Compensation of up to $150 will be provided based on completed visits.
Inclusion Criteria:
- Healthy male and female subjects between the ages 18 to 50
- Fitzpatrick skin types I through VI (all skin types)
- Moderate or severe melasma
- Willing to participate in study photography
- Able and willing to comply with all visit, treatment, and evaluation schedules
- Able to understand and provide written informed consent
Exclusion Criteria:
- Pregnant, nursing women, current use of hormonal birth control medication or any hormonal therapy, or history of >2 spontaneous abortions
- Use of topical steroids on the face within 1 month of study enrollment, use of topical hydroquinone on the face within 3 months of study enrollment, laser or dermabrasion to the face within 6 months of study enrollment
- Regular use of tanning parlors, or occupation involving primarily outdoor activities
- Current treatment with blood thinning medications
- History of thrombosis, thrombophilia, or thromboembolic disease, such as deep vein thrombosis, pulmonary embolism and/or cerebral thrombosis, family history of thromboembolic disease
- History of seizures or known light sensitive seizure disorder, stroke, or subarachnoid hemorrhage
- History of kidney dysfunction
- History of cancer, or active smoking
- Significant cardiovascular or respiratory disease (end-stage congestive heart failure or chronic obstructive pulmonary disease)
- History of acquired disturbances of color vision
- Known allergy to tranexamic acid
- As per the investigator’s discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study
For More Information Contact The Research Department At
713-900-3900 or info@dermlasersugery.com